• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20072 / SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine...

SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor

5 July 2007/in 2007, News

SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2007-07-05 13:17:372016-11-28 13:43:25SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board Link to: SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board Link to: 2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples Link to: 2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples 2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Sample...
Scroll to top Scroll to top Scroll to top